The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Celyad Oncology's share price is $0.25.
Celyad Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00. Hence, Celyad Oncology's PS Ratio for today is .
The historical rank and industry rank for Celyad Oncology's PS Ratio or its related term are showing as below:
During the past 13 years, Celyad Oncology's highest PS Ratio was 1053.18. The lowest was 1.28. And the median was 37.43.
CLYYF's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.29 * Ranked among companies with meaningful PS Ratio only.
During the past 13 years, Celyad Oncology's highest 3-Year average Revenue per Share Growth Rate was 155.70% per year. The lowest was 76.50% per year. And the median was 116.10% per year.
Back to Basics: PS Ratio
Celyad Oncology (OTCPK:CLYYF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Celyad Oncology PS Ratio Related Terms
Celyad Oncology PS Ratio Historical Data
* Premium members only.
The historical data trend for Celyad Oncology's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Celyad Oncology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celyad Oncology PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celyad Oncology's PS Ratio distribution charts can be found below:
* The bar in red indicates where Celyad Oncology's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Celyad Oncology's Share Price of today is $0.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Celyad Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Based on GuruFocus' analysis, Celyad Oncology stock appears to be undervalued.
The current stock price of $0.25 is trading 43.2% below its estimated GF Value™ of $0.44.
Key valuation signals for CLYYF:
PS Ratio:
GF Value™: $0.44 vs. price of $0.25 (43.2% below fair value)
No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
13GF Score
Get the complete analysis for CLYYF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYYF has been successfully added to your 
